Literature DB >> 7833562

Epidemiology of pediatric human immunodeficiency virus infection in the United States.

M F Rogers1, M B Caldwell, M L Gwinn, R J Simonds.   

Abstract

Human Immunodeficiency Virus (HIV) infection is a growing problem for children worldwide. As of 31 December 1992, 4249 children with Acquired Immunodeficiency Syndrome (AIDS) under 13 years of age had been reported to the US Centers for Disease Control and Prevention (CDC). HIV is transmitted to children predominantly from their mothers. Nearly all cases of HIV infection acquired from blood transfusions in the United States occurred before donor-screening practices were implemented in March 1985. In 1991, approximately 7000 HIV-infected women gave birth to a liveborn infant in the United States, for a prevalence of 1.7 per 1000 women. Despite recent advances in prophylactic therapy for opportunistic infections, Pneumocystis carinii pneumonia remains the most common AIDS-defining illness in children in the United States. If these cases are to be prevented, children born to HIV-infected mothers will need to be identified early and monitored appropriately for CD4+ cell counts to determine the need for prophylaxis.

Entities:  

Mesh:

Year:  1994        PMID: 7833562     DOI: 10.1111/j.1651-2227.1994.tb13324.x

Source DB:  PubMed          Journal:  Acta Paediatr Suppl        ISSN: 0803-5326


  3 in total

1.  Opportunistic Infections and Complications in Human Immunodeficiency Virus-1-Infected Children: Correlation with immune status.

Authors:  Jaivinder Yadav; Sanjeev Nanda; Deepak Sharma
Journal:  Sultan Qaboos Univ Med J       Date:  2014-10-14

Review 2.  Sexually transmitted diseases in sexually abused children: medical and legal implications.

Authors:  M R Hammerschlag
Journal:  Sex Transm Infect       Date:  1998-06       Impact factor: 3.519

3.  Leukemia inhibitory factor inhibits HIV-1 replication and is upregulated in placentae from nontransmitting women.

Authors:  B K Patterson; H Behbahani; W J Kabat; Y Sullivan; M R O'Gorman; A Landay; Z Flener; N Khan; R Yogev; J Andersson
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.